University of California San Francisco Comprehensive Cancer Center — San Francisco, California

University of California San Francisco Comprehensive Cancer Center is a clinical research site located in San Francisco, California, United States 94115.

Crixeo Health Trust Score: 72/100 (FAIR). This profile has not yet been claimed by the site owner.

University of California San Francisco Comprehensive Cancer Center has participated in 8 clinical trials with 1 currently active.

Therapeutic areas: Carcinoma, Renal Cell, Breast Cancer, Metastatic Breast Cancer.

Sponsors: Attenuon, Accelerated Community Oncology Research Network, Veru Inc..

Sponsor Feasibility Report

Trust Score: 72/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of California San Francisco Comprehensive Cancer Center?

University of California San Francisco Comprehensive Cancer Center has a Crixeo Trust Score of 72/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of California San Francisco Comprehensive Cancer Center conducted?

University of California San Francisco Comprehensive Cancer Center has 8 clinical trials on record, with 1 currently active. Their work covers Carcinoma, Renal Cell, Breast Cancer, Metastatic Breast Cancer.

Is University of California San Francisco Comprehensive Cancer Center accredited by Crixeo Health?

Yes — University of California San Francisco Comprehensive Cancer Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about University of California San Francisco Comprehensive Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.